drugset / Trial / NCT02699710
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
This study is a Phase I, single center, randomized (Parts 1 and 2 only), open-label, 3 part study. Parts 1 and 2 are 2-way crossover, with 1-fixed sequence, 3-period designs to investigate the effect of formulation, food and rabeprazole on the PK of GDC-0853 in healthy male and female (of non-childbearing potential) participants. Part 3 is a fixed-sequence study with 3 treatments to characterize the steady-state PK of the GDC-0853 tablet; the effect of simultaneous administration of a single dose of methotrexate on the steady-state kinetics of GDC-0853; and the effect of dosing GDC-0853 to steady-state on the single dose PK of methotrexate in healthy male participants.
Timeline
- Start
- 2015-09-03
- Primary completion
- 2016-05-26
- Completion
- 2016-05-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fenebrutinib | Small molecule | 200 mg | Oral |
| Subject | Methotrexate | Small molecule | 7.5 mg | Oral |
| Background | Rabeprazole | Small molecule | 20 mg | Oral |
| Background | folic acid | Other / unclassified | 5 mg | Oral |
Indications
No indication recorded.